High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition

Morten M Poulsen; Poul Frølund Vestergaard; Berthil F Clasen; Yulia Radko; Lars P Christensen; Hans Stødkilde-Jørgensen; Niels Møller; Niels Jessen; Steen Bønløkke Pedersen; Jens Otto Lunde Jørgensen

doi:10.2337/db12-0975

High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition

Morten M Poulsen, Poul Frølund Vestergaard, Berthil F Clasen, Yulia Radko, Lars P Christensen, Hans Stødkilde-Jørgensen, Niels Møller, Niels Jessen, Steen Bønløkke Pedersen, Jens Otto Lunde Jørgensen

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

412 Citations (Scopus)

Abstract

Obesity, diabetes, hypertension, and hyperlipidemia constitute risk factors for morbidity and premature mortality. Based on animal and in vitro studies, resveratrol reverts these risk factors via stimulation of silent mating type information regulation 2 homolog 1 (SIRT1), but data in human subjects are scarce. The objective of this study was to examine the metabolic effects of high-dose resveratrol in obese human subjects. In a randomized, placebo-controlled, double-blinded, and parallel-group design, 24 obese but otherwise healthy men were randomly assigned to 4 weeks of resveratrol or placebo treatment. Extensive metabolic examinations including assessment of glucose turnover and insulin sensitivity (hyperinsulinemic euglycemic clamp) were performed before and after the treatment. Insulin sensitivity, the primary outcome measure, deteriorated insignificantly in both groups. Endogenous glucose production and the turnover and oxidation rates of glucose remained unchanged. Resveratrol supplementation also had no effect on blood pressure; resting energy expenditure; oxidation rates of lipid; ectopic or visceral fat content; or inflammatory and metabolic biomarkers. The lack of effect disagrees with persuasive data obtained from rodent models and raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders.

Original language	English
Journal	Diabetes
Volume	62
Issue	4
Pages (from-to)	1186-1195
Number of pages	10
ISSN	0012-1797
DOIs	https://doi.org/10.2337/db12-0975
Publication status	Published - 2013

Access to Document

10.2337/db12-0975

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609591/pdf

Cite this

Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. L. (2013). High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition. Diabetes, 62 (4), 1186-1195. https://doi.org/10.2337/db12-0975

@article{e6d2b45452c9452099c47b3bf1f9fba8,

title = "High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition",

abstract = "Obesity, diabetes, hypertension, and hyperlipidemia constitute risk factors for morbidity and premature mortality. Based on animal and in vitro studies, resveratrol reverts these risk factors via stimulation of silent mating type information regulation 2 homolog 1 (SIRT1), but data in human subjects are scarce. The objective of this study was to examine the metabolic effects of high-dose resveratrol in obese human subjects. In a randomized, placebo-controlled, double-blinded, and parallel-group design, 24 obese but otherwise healthy men were randomly assigned to 4 weeks of resveratrol or placebo treatment. Extensive metabolic examinations including assessment of glucose turnover and insulin sensitivity (hyperinsulinemic euglycemic clamp) were performed before and after the treatment. Insulin sensitivity, the primary outcome measure, deteriorated insignificantly in both groups. Endogenous glucose production and the turnover and oxidation rates of glucose remained unchanged. Resveratrol supplementation also had no effect on blood pressure; resting energy expenditure; oxidation rates of lipid; ectopic or visceral fat content; or inflammatory and metabolic biomarkers. The lack of effect disagrees with persuasive data obtained from rodent models and raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders.",

author = "Poulsen, {Morten M} and Vestergaard, {Poul Fr{\o}lund} and Clasen, {Berthil F} and Yulia Radko and Christensen, {Lars P} and Hans St{\o}dkilde-J{\o}rgensen and Niels M{\o}ller and Niels Jessen and Pedersen, {Steen B{\o}nl{\o}kke} and J{\o}rgensen, {Jens Otto Lunde}",

year = "2013",

doi = "10.2337/db12-0975",

language = "English",

volume = "62 ",

pages = "1186--1195",

journal = "Diabetes",

issn = "0012-1797",

publisher = "American Diabetes Association Inc.",

number = "4",

}

Poulsen, MM, Vestergaard, PF, Clasen, BF, Radko, Y, Christensen, LP, Stødkilde-Jørgensen, H, Møller, N , Jessen, N , Pedersen, SB & Jørgensen, JOL 2013, 'High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition', Diabetes, vol. 62 , no. 4, pp. 1186-1195. https://doi.org/10.2337/db12-0975

High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition. / Poulsen, Morten M; Vestergaard, Poul Frølund; Clasen, Berthil F et al.
In: Diabetes, Vol. 62 , No. 4, 2013, p. 1186-1195.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - High-Dose Resveratrol Supplementation in Obese Men

T2 - An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition

AU - Poulsen, Morten M

AU - Vestergaard, Poul Frølund

AU - Clasen, Berthil F

AU - Radko, Yulia

AU - Christensen, Lars P

AU - Stødkilde-Jørgensen, Hans

AU - Møller, Niels

AU - Jessen, Niels

AU - Pedersen, Steen Bønløkke

AU - Jørgensen, Jens Otto Lunde

PY - 2013

Y1 - 2013

N2 - Obesity, diabetes, hypertension, and hyperlipidemia constitute risk factors for morbidity and premature mortality. Based on animal and in vitro studies, resveratrol reverts these risk factors via stimulation of silent mating type information regulation 2 homolog 1 (SIRT1), but data in human subjects are scarce. The objective of this study was to examine the metabolic effects of high-dose resveratrol in obese human subjects. In a randomized, placebo-controlled, double-blinded, and parallel-group design, 24 obese but otherwise healthy men were randomly assigned to 4 weeks of resveratrol or placebo treatment. Extensive metabolic examinations including assessment of glucose turnover and insulin sensitivity (hyperinsulinemic euglycemic clamp) were performed before and after the treatment. Insulin sensitivity, the primary outcome measure, deteriorated insignificantly in both groups. Endogenous glucose production and the turnover and oxidation rates of glucose remained unchanged. Resveratrol supplementation also had no effect on blood pressure; resting energy expenditure; oxidation rates of lipid; ectopic or visceral fat content; or inflammatory and metabolic biomarkers. The lack of effect disagrees with persuasive data obtained from rodent models and raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders.

AB - Obesity, diabetes, hypertension, and hyperlipidemia constitute risk factors for morbidity and premature mortality. Based on animal and in vitro studies, resveratrol reverts these risk factors via stimulation of silent mating type information regulation 2 homolog 1 (SIRT1), but data in human subjects are scarce. The objective of this study was to examine the metabolic effects of high-dose resveratrol in obese human subjects. In a randomized, placebo-controlled, double-blinded, and parallel-group design, 24 obese but otherwise healthy men were randomly assigned to 4 weeks of resveratrol or placebo treatment. Extensive metabolic examinations including assessment of glucose turnover and insulin sensitivity (hyperinsulinemic euglycemic clamp) were performed before and after the treatment. Insulin sensitivity, the primary outcome measure, deteriorated insignificantly in both groups. Endogenous glucose production and the turnover and oxidation rates of glucose remained unchanged. Resveratrol supplementation also had no effect on blood pressure; resting energy expenditure; oxidation rates of lipid; ectopic or visceral fat content; or inflammatory and metabolic biomarkers. The lack of effect disagrees with persuasive data obtained from rodent models and raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders.

U2 - 10.2337/db12-0975

DO - 10.2337/db12-0975

M3 - Journal article

C2 - 23193181

SN - 0012-1797

VL - 62

SP - 1186

EP - 1195

JO - Diabetes

JF - Diabetes

IS - 4

ER -

High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition

Abstract

Access to Document

Fingerprint

Cite this